Tevogen Inc. (TVGN) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company was founded in 2020 and is based in Warren, New Jersey.
No case yet. It builds on the next filing, report or 13F period.
Tevogen Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
High 8.25 at 7:15 am ET, low 6.99 at 4:00 am ET.
The one company Tevogen Bio Holdings Inc. moves with most closely does not share its SEC classification.
Measured against 134 trading days of our own closes. Co-movement, not cause.
SIC 2836, Biological Products, (No Diagnostic Substances), from each company's own filings. Largest first.
tall tick = annual report · 1 on record
TVGN (Tevogen Inc.) has 0 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
12 managers report a position worth $40,537 between them, and 1 of them hold 80% of it.